SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a top trending stock as the community discusses its oral obesity drug VK2735 advancing directly to Phase 3, a move expected to accelerate its market entry and enhance its competitive stance in the rapidly expanding GLP-1 sector, especially with recent favorable regulatory developments against compounded alternatives.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending with its imminent merger into quantum technology leader Infleqtion, driven by recent NASA and DOE contracts, validating its technology. The community is actively discussing its significant undervaluation compared to sector peers and anticipating its debut on the NYSE as INFQ, with many seeing current price action as a prime buying opportunity.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is at the forefront of community discussion after initiating its Eagle Line pilot production and shipping B-samples to multiple automotive OEMs, intensifying speculation around upcoming commercialization timelines and potential partnerships for its groundbreaking solid-state battery technology.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending following the unexpected early FDA approval of Optune Pax for locally advanced pancreatic cancer, which is being hailed as a significant breakthrough and the first new treatment in decades for this high-need cancer. The community is actively discussing its substantial revenue potential and the possibility of a short squeeze, while some remain cautious regarding the modest survival extension and historical execution challenges.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is trending after reporting strong earnings and raising full-year guidance, attributing growth to surging AI infrastructure orders; however, the community is debating its valuation and gross margin outlook, which is impacted by rising memory costs, despite its pivotal role in the AI buildout.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management system, as well as other tools, integrations and native payment solutions. It operates through the following geographical segments: Americas, Europe and Asia Pacific. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is actively discussed following its Q4 earnings report, which showed strong performance and a $1 billion share repurchase program, yet the stock saw a sharp decline, fueling a community divide between those highlighting its value and others fearing "Death By AI" disruption across the software sector.

Porch Group, Inc. engages in the development and operation of a vertical software platform. It operates through Vertical Software and Insurance segments. The Vertical Software segment provides software and services to home services companies, such as home inspectors, mortgage companies and loan officers, title companies, moving companies, real estate agencies, utility companies, and others. The Insurance segment operates both as an insurance carrier underwriting home insurance policies, and as agent selling home and auto insurance and also includes porch's warranty service offering. The company was founded by Matt Ehrlichman & Ronnie Castro in 2011 and is headquartered in Seattle, WA.

Porch Group Inc - Ordinary Shares - Class A

Porch Group is seeing a surge in conversation and trading volume after its strong earnings report highlighted improved profitability and significant cash flow from its reciprocal insurance model, fueling positive analyst upgrades and community optimism about its long-term prospects.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending following a strong earnings report that delivered record revenue, gross margin, and operating profit, with bullish 2026 guidance driven by significant security growth and emerging AI tailwinds. The community is buzzing with anticipation for further upside and short covering, marking a potential turnaround despite some long-term investors advising caution on volatility.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as excitement builds for the highly anticipated R2, with positive initial reviews and forthcoming pricing details on March 12 highlighting its potential as a mass-market EV competitor. The community is sharply divided, with optimists hailing the R2 as a game-changer for profitability, while skeptics remain concerned about execution and cash burn ahead of this week's earnings.

DeepBook was built from the ground up to power the Sui ecosystem with unparalleled liquidity. From its inception, it has provided developers with reliable, composable on-chain applications, and enabled market makers and liquidity pools to operate seamlessly within the blockchain world.  As a community-driven public good, DeepBook has integrated with top DEXs and aggregators since Sui's mainnet launch, enhancing dApps with efficient, censorship-free liquidity. This synergy of orderbook efficiency and blockchain transparency positions DeepBook as the premier liquidity venue in web3.

DeepBook

Deep Crypto (DEEP) is trending as recent major exchange listings and the launch of a Grayscale DeepBook Trust drive significant trading volume and community discussion. Investors are focused on its pivotal role as the liquidity backbone of the rapidly expanding Sui Network, highlighting its deflationary tokenomics and attractive DeFi opportunities, including high staking rewards and negative borrow interest rates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ovid Therapeutics $OVID Position Cut by TLS Advisors LLC

TLS Advisors LLC lowered its holdings in shares of Ovid Therapeutics (NASDAQ:OVID - Free Report) by 97.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Ovid Therapeutics (NASDAQ:OVID) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered Ovid Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold"

Wall Street Zen upgraded Ovid Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

FY2025 Earnings Forecast for OVID Issued By Lifesci Capital

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities researchers at Lifesci Capital issued their FY2025 earnings estimates for Ovid Therapeutics in a research report issued on Monday, December...

Ovid Therapeutics (NASDAQ:OVID) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital assumed coverage on shares of Ovid Therapeutics in a research report on Monday. They set an "outperform" rating and a $4.00 price objective for the company...

Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated a "buy" rating and issued a $2.00 price objective on shares of Ovid Therapeutics in a research report on Monday...

Ovid Therapeutics (NASDAQ:OVID) Upgraded at Roth Capital

Roth Capital raised shares of Ovid Therapeutics to a "strong-buy" rating in a research note on Thursday...

Ovid Therapeutics Names Petra Kaufmann Chief Medical Officer

(RTTNews) - Ovid Therapeutics Inc. (OVID) on Tuesday announced the appointment of Petra Kaufmann as its chief medical officer...

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been given a consensus rating of "Buy" by the nine analysts that are presently covering the stock, Marketbeat reports. One analyst has...

William Blair Issues Pessimistic Forecast for OVID Earnings

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Stock analysts at William Blair cut their FY2025 EPS estimates for Ovid Therapeutics in a research note issued to investors on Wednesday, November...

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During on April 1, 2014 and is headquartered in New York, NY.

Ovid Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

Current Price	$1.59
Prev Close	$1.64
Open	$1.66
Dividend Yield	0.00%
50-Day Moving Average	$1.63
Beta	1.18
Avg. Volume	1.62M
PE Ratio	-3.21

52-Week High	$2.01
52-Week Low	$0.2425
Market Capitalization	$213.5M
EPS (Annual)	-$0.3728
Price to Book	2.61
Revenue Per Employee	$24,608.70

OVID
Ovid Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OVID News

OVIDOvid Therapeutics Inc